231 results on '"Balshaw, R."'
Search Results
2. Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project
3. Efficiency Lost By Analyzing Counts Rather Than Event Times in Poisson and Overdispersed Poisson Regression Models
4. Predictive Ability of Pretransplant Comorbidities to Predict Long-Term Graft Loss and Death
5. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
6. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3
7. Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis
8. Two-Hour Post-Dose Cyclosporine Levels in Renal Transplantation in Argentina: A Cost-Effective Strategy for Reducing Acute Rejection
9. A MATCHED COHORT PHARMACOEPIDEMIOLOGICAL ANALYSIS OF STEROID FREE IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: 054
10. exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin
11. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
12. Predictive value of class I and class II anti-HLA antibodies in renal transplantation: P-278
13. Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation
14. META-ANALYSIS OF THE EFFICACY OF THE FENTANYL HCL IONTOPHORETIC TRANSDERMAL SYSTEM (ITS) VERSUS IV PCA IN POST-OPERATIVE ACUTE PAIN MANAGEMENT: 717
15. Outcome on quality of life in a Canadian national sample of patients with schizophrenia and related psychotic disorders
16. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders
17. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia
18. The Canadian National Outcomes Measurement Study in Schizophrenia: overview of the patient sample and methodology
19. THE ECONOMIC EVALUATION OF IMMUNOSUPPRESSIVE REGIMENS WITH FTY720 AND NEORAL VS. MYCOPHENOLATE AND NEORAL FOR RENAL TRANSPLANTATION
20. Revision of the Kidney Transplant Questionnaire (KTQ) for Measurement of Health Related Quality of Life (HRQoL)
21. Quality of Life Assessment in a Non-Randomized Study of Rheumatoid Arthritis: The Use of the Propensity Score to Correct for Imbalanced Treatment Assignments
22. P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling
23. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.
24. (48) - Plasma Protein Biosignatures for Detection of Cardiac Allograft Vasculopathy
25. (50) - Blood Test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation
26. Molecular signatures of end-stage heart failure.
27. Patients in Australian Memory Clinics: baseline characteristics and predictors of decline at six months.
28. The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada.
29. Identifying HCV genotype 1 patients at risk of relapse.
30. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin.
31. Inadequate pain relief (IPR) in knee osteoarthritis: what does it look like? a European survey of osteoarthritis real world therapies (SORT)
32. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
33. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.
34. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
35. PMS59 Inadequate Pain Relief in Knee Osteoarthritis and Patient Reported outcomes: A Survey of Osteoarthritis Real World Therapies (SORT) in the United Kingdom
36. T502 INADEQUATE PAIN RELIEF IN KNEE OSTEOARTHRITIS: AN EARLY LOOK AT THE SURVEY OF OSTEOARTHRITIS REAL WORLD THERAPIES (SORT)
37. RESOURCE UTILIZATION COSTS IN PSYCHOTIC PATIENTS: THE CANADIAN OSCAR STUDY
38. 717 META-ANALYSIS OF THE EFFICACY OF THE FENTANYL HCL IONTOPHORETIC TRANSDERMAL SYSTEM (ITS) VERSUS IV PCA IN POST-OPERATIVE ACUTE PAIN MANAGEMENT
39. PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A
40. PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION
41. PMH4 2-YEAR OUTCOMES OF RISPERDAL® CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA
42. PMH12: THE COST OF TREATING SCHIZOPHRENIA IN ROUTINE CLINICAL PRACTICE: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA (CNOMSS)
43. Risk of adverse events associated with antipsychotic treatment — Results from the Canadian national outcomes measurement study in schizophrenia
44. TWO-HOUR POST-DOSE CYCLOSPORINE LEVELS IN RENAL TRANSPLANTATION IN ARGENTINA: A COST-EFFECTIVE STRATEGY FOR REDUCING ACUTE REJECTION.
45. A PROTEOMIC BIOMARKER PIPELINE FROM DISCOVERY TO THE CLINIC: VALIDATION IN CARDIAC TRANSPLANTATION.
46. BIOMARKERS OF CHRONIC HEART ALLOGRAFT REJECTION.
47. TARGETED WHOLE BLOOD GENOMIC DIAGNOSTIC BIOMARKER DISCOVERY OF ACUTE HEART REJECTION.
48. EXPLORATORY AND INFERENTIAL STATISTICS FOR THE DISCOVERY OF PROTEOMIC BIOMARKERS OF ACUTE KIDNEY ALLOGRAFT REJECTION.
49. REFINEMENT OF GENOMIC CLASSIFIERS FOR EARLY ACUTE RENAL ALLOGRAFT REJECTION.
50. CLASSIFICATION OF ACUTE RENAL REJECTION WITH PROTEOGENOMIC ENSEMBLE CLASSIFIERS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.